The Economic Impact of Rectal Cancer: A Population-Based Study in Italy


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
08 01 2021
Historique:
received: 19 10 2020
revised: 02 01 2021
accepted: 04 01 2021
entrez: 12 1 2021
pubmed: 13 1 2021
medline: 18 3 2021
Statut: epublish

Résumé

Costs of cancer care are increasing worldwide, and sustainability of cancer burden is critical. In this study, the economic impact of rectal cancer on the Italian healthcare system, measured as public healthcare expenditure related to investigation and treatment of rectal cancer patients is estimated. A cross-sectional cohort of 9358 rectal cancer patients is linked, on an individual basis, to claims associated to rectal cancer diagnosis and treatments. Costs refer mainly to years 2010-2011 and are estimated by phase of care, as healthcare needs vary along the care pathway: diagnostic procedures are mainly provided in the first year, surveillance procedures are addressed to chronically ill patients, and end-of-life procedures are given in the terminal status. Clinical approaches and corresponding costs are specific by cancer type and vary by phase of care, stage at diagnosis, and age. Surgery is undertaken by the great majority of patients. Thus, hospitalization is the main cost driver. The evidence produced can be used to improve planning and allocation of healthcare resources. In particular, early diagnosis of rectal cancer is a gain in healthcare budget. Policies raising spreading of and adherence to screening plans, above all when addressed to people living in Southern Italy, should be strongly encouraged.

Identifiants

pubmed: 33430156
pii: ijerph18020474
doi: 10.3390/ijerph18020474
pmc: PMC7827442
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):561-70
pubmed: 23535024
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2006-14
pubmed: 21980008
J Natl Cancer Inst Monogr. 2013;2013(46):62-78
pubmed: 23962510
Br J Cancer. 2016 May 24;114(11):1286-92
pubmed: 27070711
Eur J Intern Med. 2018 Aug;54:13-16
pubmed: 29514743
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
BMC Cancer. 2016 Oct 18;16(1):809
pubmed: 27756310
Acta Oncol. 2015 Apr;54(4):454-62
pubmed: 25519708
BMC Health Serv Res. 2017 Jan 26;17(1):84
pubmed: 28122558
J Natl Cancer Inst. 2008 May 7;100(9):630-41
pubmed: 18445825
J Natl Cancer Inst Monogr. 2013;2013(46):88-98
pubmed: 23962512
Int J Evid Based Healthc. 2017 Jun;15(2):53-62
pubmed: 28157723
Med Care. 2015 Apr;53(4):302-9
pubmed: 25749656
Lancet Oncol. 2011 Sep;12(10):933-80
pubmed: 21958503
J Natl Compr Canc Netw. 2018 Apr;16(4):402-410
pubmed: 29632060
Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):35-44
pubmed: 24328809
Clin Colorectal Cancer. 2016 Dec;15(4):277-284
pubmed: 27521066
Acta Oncol. 2018 Jul;57(7):983-988
pubmed: 29451406
Epidemiol Prev. 2012 Nov-Dec;36(6 Suppl 1):55-77
pubmed: 23293271
Eur J Cancer. 2016 Oct;66:162-70
pubmed: 27589247
Asian Pac J Cancer Prev. 2012;13(2):421-5
pubmed: 22524800
BMC Cancer. 2013 Jul 05;13:329
pubmed: 23826976
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
CMAJ Open. 2018 Jan 4;6(1):E1-E10
pubmed: 29301745
S Afr Med J. 2016 Sep 06;106(10):949-950
pubmed: 27725010
Oncotarget. 2017 May 9;8(42):71548-71555
pubmed: 29069727
Cancer. 2017 Apr 15;123(8):1313-1323
pubmed: 28182258
Ann Oncol. 2014 Nov;25(11):2251-2260
pubmed: 25149707
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Ann Oncol. 2013 Nov;24(11):2897-902
pubmed: 24078620
Int J Environ Res Public Health. 2020 Jul 02;17(13):
pubmed: 32630745
BMC Cancer. 2018 Feb 9;18(1):169
pubmed: 29426306
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614

Auteurs

Anna Gigli (A)

Institute for Research on Population and Social Policies, National Research Council, 00185 Rome, Italy.

Silvia Francisci (S)

Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, 00161 Roma, Italy.

Giulia Capodaglio (G)

Servizio Epidemiologico Regionale, Azienda Zero, 35132 Padova, Italy.

Daniela Pierannunzio (D)

Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, 00161 Roma, Italy.

Sandra Mallone (S)

Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, 00161 Roma, Italy.

Andrea Tavilla (A)

Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, 00161 Roma, Italy.

Tania Lopez (T)

Centro Nazionale per la Prevenzione delle Malattie e la Promozione della Salute, Istituto Superiore di Sanità, 00161 Roma, Italy.

Manuel Zorzi (M)

Registro Tumori Veneto, Azienda Zero, 35132 Padova, Italy.

Fabrizio Stracci (F)

Registro Tumori dell'Umbria, Università di Perugia, 06123 Perugia, Italy.

Susanna Busco (S)

UOC Programmazione e Controllo di Gestione, Azienda Sanitaria Locale Latina, 04100 Latina, Italy.

Walter Mazzucco (W)

Registro Tumori di Palermo, Università of Palermo, 90133 Palermo, Italy.

Sara Lonardi (S)

Istituto Oncologico Veneto, IRCCS, 35128 Padova, Italy.

Fortunato Bianconi (F)

Registro Tumori dell'Umbria, Università di Perugia, 06123 Perugia, Italy.

Antonio Giampiero Russo (AG)

Registro Tumori di Milano, Agenzia per la Protezione della Salute di Milano, 20100 Milano, Italy.

Silvia Iacovacci (S)

Registro Tumori di Latina, Dipartimento di Prevenzione Azienda Sanitaria Locale Latina, 04100 Latina, Italy.

Diego Serraino (D)

Registro Tumori del Friuli Venezia Giulia, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy.

Gianfranco Manneschi (G)

Registro Tumori della Toscana, Istituto per lo Studio, la Prevenzione e la Rete Oncologica, 50139 Firenze, Italy.

Mario Fusco (M)

Registro Tumori Azienda Sanitaria Locale Napoli 3 Sud, 80100 Napoli, Italy.

Rosanna Cusimano (R)

Azienda Sanitaria Locale 6, 90141 Palermo, Italy.

Massimo Rugge (M)

Registro Tumori del Veneto, Università di Padova, 35122 Padova, Italy.

Stefano Guzzinati (S)

Registro Tumori Veneto, Azienda Zero, 35132 Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH